Top Pharmaceutical Companies in NYC, NY (214)

Product Line Growth: Newer and acquired medicines grew 18% operationally in Q2 2026, while revenue excluding Comirnaty and Paxlovid rose 5% operationally in the same period. Excluding COVID products, 2025 revenue also increased 6% operationally, supported by growth in products such as Eliquis and Padcev.

Cost & Operational Efficiency: Management is pursuing additional savings to improve operational efficiency and support profitability. These cost-control efforts are intended to help the business transition away from pandemic-driven sales while supporting margins.

Innovation-Driven Growth: Investment in future growth includes $10.4 billion in internal R&D during 2025 and ongoing development in oncology and obesity. A broad pipeline and recent acquisitions are intended to offset declining COVID-19 sales and patent expirations if programs succeed.

Strong Revenue Growth: Sacra estimates indicate revenue rose from about $360M in 2023 to roughly $598M in 2024, a sharp increase attributed largely to Ro Body. This points to accelerated top-line momentum rather than mere product proliferation.

Market Expansion: Launches such as the nationwide Wegovy pill on January 5, 2026 and additional obesity-care offerings suggest broader reach across treatment categories and patient segments. Reuters also describes an influx of new customers with the oral Wegovy launch, including men who avoided injections.

Strategic Partnerships: Announcements document direct collaborations with Novo Nordisk on Wegovy and Eli Lilly on Zepbound, alongside a research tie-up with Amgen. These relationships expand access to branded therapies and reinforce distribution relevance in obesity care.

Investor Backing & Capital Strength: Capital raising includes a $372 million Series D in 2024 with participation from Sanofi, bringing total funding above $600 million. The stated use of proceeds was to expand the drug pipeline and AI platform, indicating a strong financial base for growth.

Product Line Growth: The portfolio has expanded through multiple in-licensing deals in 2025–2026 and now spans preclinical, Phase 1, and Phase 2 programs. Tangible execution includes dosing the first participant in the BLKR201 Phase 1 trial in June 2026, only months after licensing the asset.

Strategic Partnerships: High-profile collaborations include work with Sanofi and OpenAI to build AI tools for drug development, alongside a Sanofi licensing agreement for gusacitinib with significant potential milestone value. These relationships reinforce external validation and create pathways to scale development.

Strong Revenue Growth: Company disclosures point to multi‑year top‑line expansion, with independent credit commentary anticipating continued gains. The scale of the installed healthcare network reinforces commercial traction over time.

Market Expansion: Recent launches of a Consumer Health Network and programmatic advertising capabilities extend reach beyond traditional pharmaceutical clients and open new buying channels. These moves indicate active growth into adjacent advertiser categories within healthcare settings.

Investor Backing & Capital Strength: A definitive agreement to be acquired by a global private‑equity firm underscores institutional confidence and adds resources to accelerate network growth and product innovation. The transaction highlights access to capital to support scaling.

Product Line Growth: Feedback suggests newer offerings like Pharma Direct and subscriptions are expanding rapidly, indicating momentum beyond the legacy prescription-discount model.

Strategic Partnerships: Feedback suggests deepening relationships with pharmaceutical manufacturers are driving strong growth in Pharma Direct and expanding medication-access programs.

Healthy Cash Flow: Feedback suggests operating cash flow was strong in recent periods, even as total revenue was near flat and segment performance was mixed.

Market Expansion: The platform’s reported research-site network scaled from hundreds in 2022 to 6,000+ sites across 50+ countries, alongside a broader base of 25+ sponsors. Feedback suggests recent partnerships helped extend reach to additional site networks.

Product Line Growth: Inato moved beyond its original marketplace into AI-powered patient pre-screening and AI site-selection, with ongoing workflow integrations. These additions indicate continued investment in broader clinical-trial capabilities.

Strategic Partnerships: Collaborations such as the RealTime eClinical Solutions agreement and integrations with CRIO and other providers are described as expanding distribution and deepening ecosystem ties. Feedback suggests these relationships open pathways to thousands of affiliated sites and embed the platform more fully in site workflows.

Strong Revenue Growth: Revenue expanded on an annual basis and continued to rise into 2026, while software annual contract value increased, indicating underlying demand. Drug discovery contributions and growing software contract activity supported the top line despite timing effects in reported software revenue.

Strategic Partnerships: Collaborations with major pharmaceutical companies and acquisition-related milestones added material revenue and visibility. These relationships complement the software business and reinforce commercial traction across discovery programs.

Investor Backing & Capital Strength: A sizable cash and securities position at mid-2026 provides runway to fund operations and product transitions. Management’s multi‑year profitability targets suggest the balance sheet can support continued investment while losses narrow.

Strong Revenue Growth: Revenue is reported to have nearly doubled during CEO Carolyn Starrett’s tenure beginning in 2021, alongside expansion of the real‑world data platform and commercial evidence services. This is the clearest direct indicator of commercial momentum even though underlying figures were not disclosed.

Market Expansion: International oncology research reach expanded markedly, with the network tripling in 2025 and then growing nearly 70% year over year by July 2026 to more than 50 sites across the UK, Germany and Japan, including a first partnership in Scotland. This points to broader geographic access and commercial reach.

Product Line Growth: Data assets and offerings have broadened, with the evidence base growing to more than six million patient records and launches such as the AI-enabled Telescope platform and expanded Panoramic datasets. These developments indicate deeper research utility and a wider product portfolio.

Strong Revenue Growth: Novartis shows multi-year sales expansion, with full-year results indicating continued top-line growth driven by priority brands across several therapeutic areas.

Profitability: Margins and operating income are described as strengthening, with core operating margin reaching about 40% alongside year-over-year core operating income growth.

Innovation-Driven Growth: Growth is supported by scaling priority brands and a deep pipeline with multiple high-value assets, alongside business development to add late- and mid-stage programs.